Renin-angiotensin system is an important factor in hormone refractory prostate cancer

Prostate

Volumn 66, Issue 8, 2006, Pages 822-830

  Uemura, Hiroji ^a   Hasumi, Hisashi ^a   Ishiguro, Hitoshi ^a   Teranishi, Jun Ichi ^a   Miyoshi, Yasuhide ^a   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor; Hormone refractory prostate cancer; Renin angiotensin system

Indexed keywords

ANDROSTANOLONE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIANDROGEN; BETA ACTIN; BICALUTAMIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE; ESTRADIOL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; ANGIOTENSIN I; ANGIOTENSIN II; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; CELL LINE, TUMOR; DEXAMETHASONE; DIHYDROTESTOSTERONE; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PEPTIDYL-DIPEPTIDASE A; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33646721799     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20407     Document Type: Article

References (49)

1. Jemal A, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics. CA Cancer J Clin 2003;53:5-26.
2. Huggins C, Hodges CV. Studies on prostate cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
3. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-1697.
4. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998;95:7379-7384.
5. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892.
6. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002;94:980-986.
7. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003;2:1139-1147.
8. Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Hasumi H, Kato /SNM> S, Kubota Y. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther 2005;4:1699-1709.
9. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y. Antiproliferative efficacy of angiotensin II receptor blocker for prostate cancer. Curr Cancer Drug Target 2005;5:307-323.
10. O'Mahony OA, Djahanbahkch O, Mahmood T, Puddefoot JR, Vinson GP. Angiotensin II in human seminal fluid. Hum Reprod 2000;15:1345-1349.
11. Fraser LR, Osiguwa OO. Human sperm responses to calcitonin, angiotensin II and fertilization-promoting peptide in prepared semen samples from normal donors and infertility patients. Hum Reprod 2004;19:596-606.
12. Fraser LR, Pondel MD, Vinson GP. Calcitonin, angiotensin II and FPP significantly modulate mouse sperm function. Mol Hum Reprod 2001;7:245-253.
13. O'Mahony OA, Barker S, Puddefoot JR, Vinson GP. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology 2004;146:392-398.
14. Hasumi H, Ishiguro H, Nakamura M, Sugiura S, Osada Y, Miyoshi Y, Fujinami K, Yao M, Kubota Y, Uemura H. Neuroserpin (pi-12) is up-regulated in high-grade prostate cancer and is associated with survival. Int J Cancer 2005;115:911-916.
15. Ishiguro H, Uemura H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin, are overexpressed and associated with prostate cancer progression. Prostate 2005;64:92-100.
16. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y. Pilot study of angiotensin II receptor blocker in advanced hormone refractory prostate cancer. Int J Clin Oncol 2005;10:405-410.
17. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004;64:7156-7168.
18. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81:242-251.
19. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005;102:6201-6206.
20. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-153.
21. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 2003;162:233-241.
22. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 2003;100:5124-5129.
23. Johnston CI. Franz Volhard Lecture. Renin-angiotensin system: A dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 1992;10:S13-S26.
24. Ellison KE, Ingelfinger JR, Pivor M, Dzau VJ. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest 1989;83:1941-1945.
25. Nicholls MG, Richards AM, Agarwal M. The importance of the renin-angiotensin system in cardiovascular disease. J Hum Hypertens 1998;12:295-299.
26. Fabiani ME, Johnston CI. Spectrum of use for the angiotensin-receptor blocking drugs. Curr Hypertens Rep 1999;1:394-401.
27. Chung O, Kuhl H, Stoll M, Unger T. Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int Suppl 1998;67:S95-S99.
28. Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens Suppl 1994;12:S3-S10.
29. Huckle WR, Earp HS. Regulation of cell proliferation and growth by angiotensin II. Prog Growth Factor Res 1994;5:177-194.
30. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996;28:803-812.
31. Lin J, Freeman MR. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells. Prostate 2003;54:1-7.
32. Tahasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999;161:317-322.
33. Chappell MC, Millsted A, Diz DI, Brosnihan KB, Ferrario CM. Evidence for an intrinsic angiotensin system in the canine pancreas. J Hypertens 1991;9:751-759.
34. Leung PS, Carlsson PO. Tissue renin-angiotensin system: Its expression, localization, regulation and potential role in the pancreas. Mol Endocrinol 2001;26:155-164.
35. Ohta T, Amaya K, Yi S, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K. Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Int J Oncol 2003;23:593-598.
36. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEES Lett 2001;495:197-200.
37. Dinh DT, Frauman AG, Casley DJ, Johnston CI, Fabiani ME. Angiotensin AT(4) receptors in the normal human prostate and benign prostatic hyperplasia. Mol Cell Endocrinol 2001;184:187-192.
38. Dinh DT, Frauman AG, Sourial M, Casley DJ, Johnston CI, Fabiani ME. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology 2001;142:1349-1356.
39. Nassis L, Frauman AG, Ohishi M, Zhuo J, Casley DJ, Johnston CI, Fabiani ME. Localization of angiotensin-converting enzyme in the human prostate: Pathological expression in benign prostatic hyperplasia. J Pathol 2001;195:571-579.
40. Dinh DT, Frauman AG, Somers GR, Ohishi M, Zhou J, Casley DJ, Johnston CI, Fabiani ME. Evidence for activation of the renin-angiotensin system in the human prostate: Increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol 2002;196:213-219.
41. Fabiani ME, Sourial M, Thomas WG, Johnston CI, Johnston CI, Frauman AG. Angiotensin II enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: Implications for the pathophysiology of benign prostatic hyperplasia. J Endocrinol 2001;171:97-108.
42. Leung PS, Chan HC, Wong PY. Immunohistochemical localization of angiotensin II in the mouse pancreas. Histochem J 1998;30:21-25.
43. Dostal DE, Baker KM. The cardiac renin-angiotensin system: Conceptual, or a regulator of cardiac function? Circ Res 1999;85:643-650.
44. Kunimoto M, Soma M, Kanmatsuse K. Production of eicosanoids and angiotensin II in resistance vessels in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1998;25:430-434.
45. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol 1997;17:412-422.
46. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992;19:456-463.
47. Jaiswal AK, Panda JN, Kumar MV, Joshi P. Androgen dependence of testicular and epididymal angiotensin converting enzyme. Andrologia 1985;17:92-97.
48. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993;43:1-20.
49. Neylon M, Marshall J, Johns EJ. The role of the renin-angiotensin system in the renal response to moderate hypoxia in the rat. J Physiol 1996;491:479-488.